AMLX - AMLX STOCK NEWS: Lead Plaintiff Deadline is Approaching in Class Action Against Amylyx Pharmaceuticals Inc.; Contact Robbins LLP for Information | Benzinga
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) securities between November 11, 2022 and November 8, 2023. Amylyx is a commercial-stage biotechnology company that engages in the discovery and development of treatments for amyotrophic lateral sclerosis ("ALS") and other neurodegenerative diseases. The Company's products include, among others, AMX0035 (commercially referred to as "RELYVRIO" in the U.S.) for the treatment of ALS in adults in the U.S.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: According to the complaint, during the class period, defendants misled investors regarding RELYVRIO's commercial prospects. Specifically, defendants failed to disclose that: (i) patients were discontinuing treatment with RELYVRIO after six months; (ii) the rate at which new patients were ...